vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Roper Technologies (ROP). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.1B, roughly 1.3× Roper Technologies). Roper Technologies runs the higher net margin — 15.8% vs -3.7%, a 19.5% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs 9.3%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $403.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 10.5%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
BHC vs ROP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.1B |
| Net Profit | $-103.0M | $331.0M |
| Gross Margin | — | 69.4% |
| Operating Margin | 17.0% | 27.2% |
| Net Margin | -3.7% | 15.8% |
| Revenue YoY | 9.3% | 11.3% |
| Net Profit YoY | -205.1% | 53.7% |
| EPS (diluted) | $-0.30 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.8B | $2.1B | ||
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.3B | $1.9B | ||
| Q4 24 | $2.6B | $1.9B | ||
| Q3 24 | $2.5B | $1.8B | ||
| Q2 24 | $2.4B | $1.7B |
| Q1 26 | — | $331.0M | ||
| Q4 25 | $-103.0M | $428.4M | ||
| Q3 25 | $179.0M | $398.5M | ||
| Q2 25 | $148.0M | $378.3M | ||
| Q1 25 | $-58.0M | $331.1M | ||
| Q4 24 | $98.0M | $462.3M | ||
| Q3 24 | $-85.0M | $367.9M | ||
| Q2 24 | $10.0M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | — | 69.5% | ||
| Q3 25 | — | 69.5% | ||
| Q2 25 | — | 69.2% | ||
| Q1 25 | — | 68.7% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 69.2% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | 27.2% | ||
| Q4 25 | 17.0% | 28.6% | ||
| Q3 25 | 23.1% | 28.4% | ||
| Q2 25 | 17.5% | 28.2% | ||
| Q1 25 | 12.2% | 27.9% | ||
| Q4 24 | 21.8% | 28.0% | ||
| Q3 24 | 12.7% | 28.1% | ||
| Q2 24 | 16.2% | 28.8% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | -3.7% | 20.8% | ||
| Q3 25 | 6.7% | 19.8% | ||
| Q2 25 | 5.8% | 19.5% | ||
| Q1 25 | -2.6% | 17.6% | ||
| Q4 24 | 3.8% | 24.6% | ||
| Q3 24 | -3.4% | 20.8% | ||
| Q2 24 | 0.4% | 19.6% |
| Q1 26 | — | $4.87 | ||
| Q4 25 | $-0.30 | $3.97 | ||
| Q3 25 | $0.48 | $3.68 | ||
| Q2 25 | $0.40 | $3.49 | ||
| Q1 25 | $-0.16 | $3.06 | ||
| Q4 24 | $0.24 | $4.29 | ||
| Q3 24 | $-0.23 | $3.40 | ||
| Q2 24 | $0.03 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $382.9M |
| Total DebtLower is stronger | $20.8B | $9.7B |
| Stockholders' EquityBook value | $-554.0M | $18.8B |
| Total Assets | $26.4B | $34.6B |
| Debt / EquityLower = less leverage | — | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | $1.3B | $297.4M | ||
| Q3 25 | $1.3B | $320.0M | ||
| Q2 25 | $1.7B | $242.4M | ||
| Q1 25 | $1.1B | $372.8M | ||
| Q4 24 | $1.2B | $188.2M | ||
| Q3 24 | $719.0M | $269.6M | ||
| Q2 24 | $595.0M | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | $20.8B | $9.3B | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | $7.6B | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — |
| Q1 26 | — | $18.8B | ||
| Q4 25 | $-554.0M | $19.9B | ||
| Q3 25 | $-565.0M | $20.0B | ||
| Q2 25 | $-764.0M | $19.6B | ||
| Q1 25 | $-1.2B | $19.2B | ||
| Q4 24 | $-1.3B | $18.9B | ||
| Q3 24 | $-1.2B | $18.5B | ||
| Q2 24 | $-1.2B | $18.1B |
| Q1 26 | — | $34.6B | ||
| Q4 25 | $26.4B | $34.6B | ||
| Q3 25 | $26.8B | $34.6B | ||
| Q2 25 | $27.3B | $33.2B | ||
| Q1 25 | $26.4B | $31.4B | ||
| Q4 24 | $26.5B | $31.3B | ||
| Q3 24 | $26.5B | $31.6B | ||
| Q2 24 | $26.5B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | — |
| Free Cash FlowOCF − Capex | $403.0M | $507.0M |
| FCF MarginFCF / Revenue | 14.4% | 24.2% |
| Capex IntensityCapex / Revenue | 3.3% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $495.0M | $738.0M | ||
| Q3 25 | $405.0M | $869.5M | ||
| Q2 25 | $289.0M | $404.1M | ||
| Q1 25 | $211.0M | $528.7M | ||
| Q4 24 | $601.0M | $722.2M | ||
| Q3 24 | $405.0M | $755.4M | ||
| Q2 24 | $380.0M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | $403.0M | — | ||
| Q3 25 | $314.0M | — | ||
| Q2 25 | $190.0M | — | ||
| Q1 25 | $96.0M | — | ||
| Q4 24 | $495.0M | — | ||
| Q3 24 | $334.0M | — | ||
| Q2 24 | $302.0M | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 14.4% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.6% | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 3.3% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | 2.26× | 2.18× | ||
| Q2 25 | 1.95× | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | 6.13× | 1.56× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | 38.00× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
ROP
Segment breakdown not available.
